jansari ☆ India, 2021-09-24 21:03 (1172 d 07:56 ago) Posting: # 22597 Views: 3,709 |
|
Dear All, As I am working in In vitro laboratory. And we are doing In-vitro binding study on Sevelamer carbonate sachets for EMA submission. My question is, whether EMA will accepts the In-vitro phosphate binding studies for generic submission like US. Is there any specific guidance documents for statistical analysis of Sevelamer carbonate for EMA Submission or can we perform statistical analysis as per USFDA guidance documents? And if we perform statistical analysis as per USFDA guidance documents(Acceptance limit for K2-80% to 120%) is it acceptable for EU submission? Is there any acceptance limit for Sevelamer carbonate product for EMA submission? A response will be highly appreciated. Thanks in advance for your help. Regards, APJ |
jansari ☆ India, 2022-05-19 22:02 (935 d 06:57 ago) @ jansari Posting: # 23004 Views: 2,621 |
|
Please help me to shortout the query on priority Your valuable response is highly appreciable.... Edit: Full quote removed. Please delete everything from the text of the original poster which is not necessary in understanding your answer; see also this post #5! [Helmut] |
dshah ★★ India, 2022-05-26 15:28 (928 d 13:32 ago) @ jansari Posting: # 23022 Views: 2,688 |
|
jansari ☆ India, 2022-05-26 21:59 (928 d 07:00 ago) @ dshah Posting: # 23025 Views: 2,596 |
|
Dear divyen, Thank you very much for providing this supporting documents to justify the query..bt this PAR published in the year 2014 and 2017..so my concern is that whether we have to justify the response with this reference docs? As EU release one guidance documents for locally acting drug in GI tract in oct 2018.this guidance is not as much clear as us fda guidance.. but in this guidance on page no. 10 stated that in vitro similarity should be assessed with +-10%acceptance limit..so similarity should be proven based on T/R ratio or 90%CI needs to b calculate? Reference doc's attached with this post.. Kindly guide on this... Thnk you in advance..... Edit: Send by email to the forum address. @Jansari: Reply directly in the forum in the future. THX. [Helmut] |
dshah ★★ India, 2022-05-27 20:40 (927 d 08:20 ago) @ jansari Posting: # 23028 Views: 2,537 |
|
Dear janasari! The link of PAR (Approved just before the Oct'18) is provided where the acceptance range is 80-120%. From guideline perspective, the 10% usually can be considered as CI. Regards, Divyen |
jansari ☆ India, 2022-05-27 20:54 (927 d 08:05 ago) @ dshah Posting: # 23029 Views: 2,622 |
|
Dear divyen, We have already gone through this PAR.bt the same it's just before published guidance..so regulatory not accept this PAR.. And it's very difficult to pass the study in this acceptance range..it's very stringent range for sevelamer carbonate..and guidance doesn't provide any methodology like USFDA.. If you have any idea and submit sevelamer study in europe Market then please guide.... Thank you very much for your prompt reply and guidance... |